Skip to main content
TipRanks
Go Ultimate75% OFF

Braveheart Bio, Inc. (BRVE) Stock Statistics & Valuation Metrics

23 Followers

Total Valuation

Braveheart Bio, Inc. has a market cap or net worth of $1.69B. The enterprise value is $1.31B.

Market Cap
$1.69B
Enterprise Value
$1.31B

Share Statistics

Braveheart Bio, Inc. has 89,870,350 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
89,870,350
Owned by Insiders
57.00%
Owned by Institutions
10.15%

Financial Efficiency

Braveheart Bio, Inc.’s return on equity (ROE) is -0.79 and return on invested capital (ROIC) is -79.36%.

Return on Equity (ROE)
-0.79
Return on Assets (ROA)
-0.75
Return on Invested Capital (ROIC)
-79.36%
Return on Capital Employed (ROCE)
-0.79
Revenue Per Employee
0
Profits Per Employee
-1.36M
Employee Count
49
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Braveheart Bio, Inc. is -6.39. Braveheart Bio, Inc.’s PEG ratio is 0.20.

PE Ratio
-6.39
PS Ratio
0.00
PB Ratio
1.93
Price to FCF
-26.84
Price to Operating Cash Flow
-20.15
PEG Ratio
0.20

Income Statement

In the last 12 months, Braveheart Bio, Inc. had revenue of 0 and earned -66.75M in profits. Earnings per share was -5.32.

Revenue
0
Gross Profit
0
Operating Income
-66.75M
Pretax Income
-66.75M
Net Income
-66.75M
EBITDA
-66.75M
Earnings Per Share (EPS)
-5.32

Cash Flow

In the last 12 months, operating cash flow was -47.78M and capital expenditures -863,000, giving a free cash flow of -48.65M billion.

Operating Cash Flow
-47.78M
Free Cash Flow
-48.65M
Free Cash Flow per Share
-0.93

Dividends & Yields

Braveheart Bio, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-3.80%
Earnings Yield
-6.60%

Stock Price Statistics

Beta
-0.04
52-Week Price Change
-36.98%
50-Day Moving Average
22.07
200-Day Moving Average
23.66
Relative Strength Index (RSI)
41.23
Average Volume (3m)
460.31K

Important Dates

Braveheart Bio, Inc. upcoming earnings date is ―, After Close (Confirmed).

Last Earnings Date
Nov 10, 2026
Next Earnings Date
―
Ex-Dividend Date
―

Financial Position

Braveheart Bio, Inc. as a current ratio of 17.03, with Debt / Equity ratio of 0.00%

Current Ratio
17.03
Quick Ratio
17.03
Debt to Market Cap
0.00
Net Debt to EBITDA
1.34
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Braveheart Bio, Inc. has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Braveheart Bio, Inc. EV to EBITDA ratio is -17.07, with an EV/FCF ratio of -23.81.

EV to Sales
0.00
EV to EBITDA
-17.07
EV to Free Cash Flow
-23.81
EV to Operating Cash Flow
-24.24

Balance Sheet

Braveheart Bio, Inc. has $349.27M in cash and marketable securities with $515.00K in debt, giving a net cash position of $348.76M billion.

Cash & Marketable Securities
$349.27M
Total Debt
$515.00K
Net Cash
$348.76M
Net Cash Per Share
$3.88
Tangible Book Value Per Share
$9.55

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Braveheart Bio, Inc. is $45.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$45.50
Price Target Upside
142.28% Upside
Analyst Consensus
Strong Buy
Analyst Count
5
Revenue Growth Forecast
―
EPS Growth Forecast
―

Scores

Smart Score
7
AI Score
―